Ribonucleic Acid News and Research

RSS

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

Echinacea, a potent antiviral against SARS-CoV-2

Researchers present available evidence on the activity of Echinacea purpure against coronavirus infections.

3 Jan 2022

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Researchers carried out an analytical susceptibility test with cultured SARS-CoV-2 Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs).

29 Dec 2021

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Researchers assess the real-world effectiveness of a third booster dose of the Pfizer-BioNTech BNT162b2 vaccine against the initial two-dose regimen.

29 Dec 2021

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

Researchers assess vaccine effectiveness of two and three doses of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admission.

28 Dec 2021

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

A new research letter evaluates whether the estimated vaccine effectiveness changes against infection over time.

28 Dec 2021

Double-dose mRNA COVID vaccines effective among dialysis patients

Researchers assess the impact of lesser initial vaccine response and subsequent waning antibody levels on clinical outcomes among maintenance dialysis.

28 Dec 2021

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

The Omicron spike is relatively poorly cleaved and impaired in mediating cell-cell fusion and syncytia formation, contrary to predictions.

28 Dec 2021

Allele-specific RT-qPCR assay to identify SARS-CoV-2 Omicron variant in wastewater

Researchers develop a new allele-specific RT-qPCR to detect the SARS-CoV-2 Omicron variant in wastewater.

23 Dec 2021

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Scientists used virus-like particles and found that Omicron showed increased infectivity, relative to the B.1 and B.1.1 strains, which was similar to the Delta variant.

23 Dec 2021

T-cell response to Omicron after an mRNA COVID vaccine booster

In a recent prospective observational study posted to the medRxiv* preprint server, researchers determined Omicron variant-associated T cell responses before and after a third dose of messenger ribonucleic acid (mRNA) vaccination against coronavirus disease (COVID-19) in anti-CD20-treated multiple sclerosis (MS) patients.

22 Dec 2021

Protein-based nanoparticle vaccines for protection against SARS-CoV-2

A recent review article discusses recent advances in protein-based nanoparticle vaccines against SARS-CoV-2.

22 Dec 2021

COVID can affect sperm quality for three months

Researchers determine whether SARS-CoV-2 could cross the blood-testis barrier and be detected in human semen after infection.

22 Dec 2021

How COVID vaccines protected Americans against the Delta variant

A new study analyzed the COVID-19 breakthrough case and death rates among fully vaccinated individuals who were 12 years of age or above.

22 Dec 2021

Role of novel SARS-CoV-2-derived svRNAs and the involvement of tRF in COVID-19

A new study revealed new long sv-COV-2 using T4 PNK pretreatment and qRT-PCR and also identified piRNAs and tRFs as the most abundant sncRNAs in COVID-19 positive samples.

22 Dec 2021

Researchers identify novel cancer markers in patients with aggressive prostate cancer

Prostate cancer is the most commonly diagnosed cancer in men and is among the top five causes of cancer-related death. In most cases, prostate cancer can be successfully treated but there is a group of patients who suffer an aggressive course and often fatal outcome.

22 Dec 2021

Ribonucleic Acid News and Research

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Minimal nAb titers against Omicron in the elderly after 3rd dose

Echinacea, a potent antiviral against SARS-CoV-2

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

Double-dose mRNA COVID vaccines effective among dialysis patients

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

Allele-specific RT-qPCR assay to identify SARS-CoV-2 Omicron variant in wastewater

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

T-cell response to Omicron after an mRNA COVID vaccine booster

Protein-based nanoparticle vaccines for protection against SARS-CoV-2

COVID can affect sperm quality for three months

How COVID vaccines protected Americans against the Delta variant

Role of novel SARS-CoV-2-derived svRNAs and the involvement of tRF in COVID-19

Researchers identify novel cancer markers in patients with aggressive prostate cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News